亚宝药业：ZY-A002药物临床试验获批

Core Viewpoint - The announcement by Yabao Pharmaceutical (600351) regarding the approval of ZY-A002 for clinical trials highlights a significant advancement in pediatric treatment for cough variant asthma, with no existing products specifically targeting this indication in the market [1] Group 1: Product Development - Yabao Pharmaceutical has received the clinical trial approval notice from the National Medical Products Administration for ZY-A002 [1] - ZY-A002 is indicated for the treatment of cough variant asthma in children, characterized by symptoms such as cough, throat itch, and minimal phlegm [1] - Currently, there are no products available in the domestic and international markets specifically designed for this pediatric indication [1]